Analyst Activity – Piper Jaffray Companies Reiterates Buy on Revance Therapeutics (NASDAQ:RVNC)

Analyst Ratings For Revance Therapeutics (NASDAQ:RVNC)

Story continues below

Today, Piper Jaffray Companies reiterated its Buy rating on Revance Therapeutics (NASDAQ:RVNC) with a price target of $28.00.

There are 1 hold rating, 3 buy ratings on the stock.

The current consensus rating on Revance Therapeutics (NASDAQ:RVNC) is Buy (Score: 2.75) with a consensus target price of $38.00 per share, a potential 59.66% upside.

Some recent analyst ratings include

  • 7/26/2017-Piper Jaffray Companies Reiterated Rating of Buy.
  • 7/20/2017-Cantor Fitzgerald initiated coverage with a Overweight rating.
  • 6/8/2017-Aegis Reiterated Rating of Buy.
  • 8/5/2016-Brean Capital Reiterated Rating of Hold.
  • 6/14/2016-Guggenheim Reiterated Rating of Buy.
  • 12/30/2015-Cowen and Company Reiterated Rating of Buy.

Recent Insider Trading Activity For Revance Therapeutics (NASDAQ:RVNC)
Revance Therapeutics (NASDAQ:RVNC) has insider ownership of 18.86% and institutional ownership of 87.29%.

  • On 5/24/2017 L Daniel Browne, CEO, sold 19,713 with an average share price of $20.35 per share and the total transaction amounting to $401,159.55. View SEC Filing
  • On 5/22/2017 L Daniel Browne, CEO, sold 12,287 with an average share price of $20.20 per share and the total transaction amounting to $248,197.40. View SEC Filing
  • On 5/22/2017 Lauren P Silvernail, CFO, sold 1,793 with an average share price of $20.20 per share and the total transaction amounting to $36,218.60. View SEC Filing
  • On 1/25/2017 L Daniel Browne, CEO, sold 12,000 with an average share price of $19.78 per share and the total transaction amounting to $237,360.00. View SEC Filing
  • On 12/28/2016 L Daniel Browne, CEO, sold 12,000 with an average share price of $20.94 per share and the total transaction amounting to $251,280.00. View SEC Filing
  • On 11/25/2016 L Daniel Browne, CEO, sold 12,000 with an average share price of $17.92 per share and the total transaction amounting to $215,040.00. View SEC Filing
  • On 10/26/2016 L Daniel Browne, CEO, sold 12,000 with an average share price of $14.85 per share and the total transaction amounting to $178,200.00. View SEC Filing

Recent Trading Activity for Revance Therapeutics (NASDAQ:RVNC)
Shares of Revance Therapeutics closed the previous trading session at 23.80 down -0.35 -1.45% with 95,627 shares trading hands.

An ad to help with our costs